Galderma has shared positive two-year data for its monoclonal antibody Nemluvio (nemolizumab) in moderate-to-severe atopic ...

Swiss skincare specialist Galderma has announced two-year data from a new interim analysis of a long-term extension study ...

Galderma (SIX: GALD) today announced two-year data from a new interim analysis of a long-term extension study investigating the saf ...

New interim two-year data from a long-term extension study of Nemluvioin atopic dermatitis reinforce its rapid onset of action and demonstrate its ...

2,4-8 The unrelenting itch of atopic dermatitis can make patients resourceful, leading them to scratch with just about anything. Galderma's "Scratch Resistance" campaign is designed to validate ...

Galderma has kicked off an ad campaign to show how its Nemluvio can empower people to rule over itchy eczema. Aiming to grow the biologic into a $2 billion product, the company is running ads ...

National TV and digital media campaign aims to motivate patients to seek treatment for relentless itch with NEMLUVIO® (nemolizumab-ilto)NEMLUVIO® (nemolizumab-ilto) ...

On Tuesday morning, Galderma launched its Scratch Resistance campaign to highlight one of the most difficult symptoms of atopic dermatitis: nonstop itching. The campaign’s ad spot features atopic ...